dry powder inhaler

Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.

dry powder inhaler (DPI),

a breath-activated device used to deliver a premeasured dose of medication by inhalation.

dry powder inhaler



An inhaler that administers tiny particles of medication to the airways. Dry powder inhalers are used to treat diseases such as asthma and chronic obstructive lung disease.
References in periodicals archive ?
There are two main types of portable inhaler devices used in the treatment of asthma and COPD: metered dose inhalers (MDIs), including pressurized MDIs (pMDIs) and breath-activated MDIs (BAIs), and dry powder inhalers (DPIs) (including single-unit dose DPIs, multi-dose reservoir DPIs and multi-unit dose DPIs).
Table 6: Budesonide Clickhaler - Assessment Of Adrenal Suppression From Two New Dry Powder Inhaler Formulations Of Budesonide Delivered By Clickhaler Compared With The Pulmicort Turbuhaler
formerly MicroDose Technologies) today announced that it has initiated a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI).
The recent trends and research in the formulating sector have grown tremendously and increased sales of dry powder inhalers (DPIs), and slowly replaced metered-dose inhalers (MDIs).
Martin, MicroDose's VP of Business Development and Licensing indicated that "the combination of Nexus6 Technology and MicroDose's dry powder inhaler will insure a continuous flow of "real time" clinical information which will benefit physicians, patients and pharmaceutical companies.
I believe Respira has developed a truly breakthrough high efficiency, lactose-free, dry powder inhaler (DPI) drug delivery technology that is poised to revolutionize the inhaled therapeutics market," said Anido.
Closer to an 'Ideal Inhaler' with the Easyhaler - an innovative dry powder inhaler.
Daiichi Sankyo Company LTD announced today that it got approval in Japan to market InavirA Dry Powder Inhaler 20mg for the prevention of influenza in both children and adults.
GlaxoSmithKline (GSK) has filed a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA dry powder inhaler.
Other subjects studied are characterization of pharmaceutical aerosols and dry powder inhalers for pulmonary drug delivery, FloDots for bioimaging and bioanalysis, and zero-valent iron nanoparticles for abatement of environmental pollutants.
According to a new market report published by Transparency Market Research " Pulmonary Drug Delivery Systems Market(Products- Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications- Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 , " the global pulmonary drug delivery systems market was valued at USD 21.